Research ExplorerPublicationsThe anti-interleukin-6 antibody siltuximab down-regulates ge...

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

Standard

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. / Karkera, Jayaprakash; Steiner, Hannes; Li, Weimin; Skradski, Viktor; Moser, Patrizia L; Riethdorf, Sabine; Reddy, Manjula; Puchalski, Thomas; Safer, Karim; Prabhakar, Uma; Pantel, Klaus; Qi, Ming; Culig, Zoran.

In: PROSTATE, Vol. 71, No. 13, 13, 2011, p. 1455-1465.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karkera, J, Steiner, H, Li, W, Skradski, V, Moser, PL, Riethdorf, S, Reddy, M, Puchalski, T, Safer, K, Prabhakar, U, Pantel, K, Qi, M & Culig, Z 2011, 'The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.', PROSTATE, vol. 71, no. 13, 13, pp. 1455-1465. <http://www.ncbi.nlm.nih.gov/pubmed/21321981?dopt=Citation>

APA

Karkera, J., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M., Puchalski, T., Safer, K., Prabhakar, U., Pantel, K., Qi, M., & Culig, Z. (2011). The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. PROSTATE, 71(13), 1455-1465. [13]. http://www.ncbi.nlm.nih.gov/pubmed/21321981?dopt=Citation

Vancouver

Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. PROSTATE. 2011;71(13):1455-1465. 13.

Bibtex

@article{5070d608f707417e94c2fdfa19071e0d,
title = "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.",
abstract = "Interleukin-6 (IL-6) is associated with prostate cancer morbidity. In several experimental models, IL-6 has been reported to have anti-apoptotic and pro-angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer.",
keywords = "Adult, Humans, Male, Aged, Middle Aged, Immunohistochemistry, Down-Regulation, Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use, Cell Transformation, Neoplastic/*genetics, *Gene Expression Regulation, Neoplastic, Interleukin-6/*antagonists & inhibitors/immunology, Neoplastic Cells, Circulating, Prostatic Neoplasms/*drug therapy/genetics/pathology, Adult, Humans, Male, Aged, Middle Aged, Immunohistochemistry, Down-Regulation, Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use, Cell Transformation, Neoplastic/*genetics, *Gene Expression Regulation, Neoplastic, Interleukin-6/*antagonists & inhibitors/immunology, Neoplastic Cells, Circulating, Prostatic Neoplasms/*drug therapy/genetics/pathology",
author = "Jayaprakash Karkera and Hannes Steiner and Weimin Li and Viktor Skradski and Moser, {Patrizia L} and Sabine Riethdorf and Manjula Reddy and Thomas Puchalski and Karim Safer and Uma Prabhakar and Klaus Pantel and Ming Qi and Zoran Culig",
year = "2011",
language = "English",
volume = "71",
pages = "1455--1465",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

RIS

TY - JOUR

T1 - The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

AU - Karkera, Jayaprakash

AU - Steiner, Hannes

AU - Li, Weimin

AU - Skradski, Viktor

AU - Moser, Patrizia L

AU - Riethdorf, Sabine

AU - Reddy, Manjula

AU - Puchalski, Thomas

AU - Safer, Karim

AU - Prabhakar, Uma

AU - Pantel, Klaus

AU - Qi, Ming

AU - Culig, Zoran

PY - 2011

Y1 - 2011

N2 - Interleukin-6 (IL-6) is associated with prostate cancer morbidity. In several experimental models, IL-6 has been reported to have anti-apoptotic and pro-angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer.

AB - Interleukin-6 (IL-6) is associated with prostate cancer morbidity. In several experimental models, IL-6 has been reported to have anti-apoptotic and pro-angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Immunohistochemistry

KW - Down-Regulation

KW - Antibodies, Monoclonal/adverse effects/pharmacokinetics/therapeutic use

KW - Cell Transformation, Neoplastic/genetics

KW - Gene Expression Regulation, Neoplastic

KW - Interleukin-6/antagonists & inhibitors/immunology

KW - Neoplastic Cells, Circulating

KW - Prostatic Neoplasms/drug therapy/genetics/pathology

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Middle Aged

KW - Immunohistochemistry

KW - Down-Regulation

KW - Antibodies, Monoclonal/adverse effects/pharmacokinetics/therapeutic use

KW - Cell Transformation, Neoplastic/genetics

KW - Gene Expression Regulation, Neoplastic

KW - Interleukin-6/antagonists & inhibitors/immunology

KW - Neoplastic Cells, Circulating

KW - Prostatic Neoplasms/drug therapy/genetics/pathology

M3 - SCORING: Journal article

VL - 71

SP - 1455

EP - 1465

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 13

M1 - 13

ER -